Genes, Vol. 11, Pages 200: Prognostic Value and Potential Regulatory Mechanism of Alternative Splicing in Geriatric Breast Cancer

Genes, Vol. 11, Pages 200: Prognostic Value and Potential Regulatory Mechanism of Alternative Splicing in Geriatric Breast Cancer Genes doi: 10.3390/genes11020200 Authors: Xin Li Yaxuan Wang Bingjie Li Wang Ma Breast cancer has the highest mortality and morbidity among women, especially in elderly women over 60 years old. Abnormal alternative splicing (AS) events are associated with the occurrence and development of geriatric breast cancer (GBC), yet strong evidence is lacking for the prognostic value of AS in GBC and the regulatory network of AS in GBC, which may highlight the mechanism through which AS contributes to GBC. In the present study, we obtained splicing event information (SpliceSeq) and clinical information for GBC from The Cancer Genome Atlas, and we constructed a GBC prognosis model based on AS events to predict the survival outcomes of GBC. Kaplan–Meier analysis was conducted to evaluate the predictive accuracy among different molecular subtypes of GBC. We conducted enrichment analysis and constructed a splicing network between AS and the splicing factor (SF) to examine the possible regulatory mechanisms of AS in GBC. We constructed eight prognostic signatures with very high statistical accuracy in predicting GBC survival outcomes from 45,421 AS events of 10,480 genes detected in 462 GBC patients; the prognostic model based on exon skip (ES) events had the highest accuracy, indicating its significant value in GBC prognosis. The construc...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research

Related Links:

Publication date: June 2020Source: Cancer Epidemiology, Volume 66Author(s): Wayne R. Lawrence, Akiko S. Hosler, Margaret Gates Kuliszewski, Matthew C. Leinung, Xiuling Zhang, Maria J. Schymura, Francis P. Boscoe
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Condition:   Hyperglycemia Drug Induced Intervention:   Biological: REMD-477 Sponsor:   Duke University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Fasting;   Breast Cancer;   Survivorship;   Breast Cancer Recurrent Intervention:   Behavioral: Fasting Sponsors:   Massachusetts General Hospital;   Kully Family Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Ovarian Cancer;   Breast Cancer Intervention:   Drug: Olaparib Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 31 March 2020Source: Life SciencesAuthor(s): Zhongqi Liu, Shi Cheng, Ganglan Fu, Fengtao Ji, Chengli Wang, Minghui Cao
Source: Life Sciences - Category: Biology Source Type: research
Purpose of review We aim to conduct a systematic review of the literature, document all reported cases of breast cancer development in cis men and female-to-male (FtM) transgender men undergoing testosterone replacement therapy (TRT), and determine if testosterone poses a substantial risk of breast cancer development and recurrence. Recent findings A systematic search through December 2019 was performed. Out of 1890, 15 studies were eligible for inclusion in the final analyses. In total, 22 patients have developed breast cancer while on testosterone treatment. Four cases were cis men, whereas 18 cases were FtM. Age ra...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: GENDER MEDICINE, INFERTILITY AND ERECTILE FUNCTION: Edited by Ryan Flannigan and Ranjith Ramasamy Source Type: research
Contributor : Yu ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDescription of breast cancer infiltrating lymphocyte through large scale single cell sequencing.While it has been well-recognized that T-cell mediated adaptive cellular immunity plays important roles in cancer immune response and tumor control, the roles of B lymphocytes in tumor development and therapy have only been proposed until recently, and are still mostly controversial. To gain mechanistic insights into the origin and dynamics of tumor infiltrated immune cells, especially B lymphocytes, we combined single ce...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Immutep reported positive data from the randomized phase IIb AIPAC clinical trial of eftilagimod alpha and paclitaxel in HER2-negative, HR-positive metastatic breast cancer (MBC).
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Contributors : Heloisa H Milioli ; Neil PortmanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHere we characterise the response of models of ER-positive breast cancer to treatment with the small molecule MDM2 inhibitor NVP-CGM097, a dihydroisoquinolinone derivative currently evaluated in a phase I clinical trial. We show that NVP-CGM097 reduces tumour cell viability of in vitro and in vivo models of endocrine sensitive, endocrine resistant and palbociclib (CDK4/6 inhibitor) resistant p53 wildtype (p53wt) ER-positive breast cancer. NVP-CGM097 synergises with both fulvestrant and palbo...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Geriatrics | Statistics | Study | Women